Adventris Pharmaceuticals
Adventris makes cancer vaccines
About Adventris Pharmaceuticals
Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths.
If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at [email protected]
Company details
Funding
Total raised
$12.5M
Last stage
Seed
Investors
Founders
Mark Yarchoan
Mark Yarchoan, M.D, is an Associate Professor of Medical Oncology at Johns Hopkins. Dr. Yarchoan runs an NCI-funded laboratory focused on developing novel immunotherapies, with a focus on cancer vaccines. He has led multiple international clinical trials of immunotherapy agents including neoantigen-targeted cancer vaccines. Dr. Yarchoan has received multiple honors, including the ASCO Young Investigator Award and the ASCO Career Development Award.
Jenny Lesser Herbach
More than a decade of biotech industry experience in oncology; previously Director of Corporate Development & Product Strategy at Amunix, and roles at InterMune and Onyx Pharmaceuticals. MBA from Harvard Business School, Masters from University of Cambridge.
LinkedInWilliam Collis
Serial entrepreneur with multiple exits, most recently the data platform Genji. MBA from Harvard Business School (Baker Scholar). Research published in Harvard Business Review and a TED talk with over 1.5M views.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.